ML100780352
| ML100780352 | |
| Person / Time | |
|---|---|
| Site: | Crane  |
| Issue date: | 12/21/2009 |
| From: | Nimitz R Engineering Region 1 Branch 2 |
| To: | Clifford J, David Lew, Darrell Roberts, Jason White Division Reactor Projects I, Division of Reactor Safety I, NRC/RGN-I/DRS/PSB2 |
| References | |
| FOIA/PA-2010-0118 | |
| Download: ML100780352 (1) | |
Text
Clifford, James From:
Nimitz, Ronald Sent:
Monday, December 21, 2009 3:51 PM To:
White, John; Roberts, Darrell; Clifford, James; Lew, David Cc:
E~arkley, Richard; Barber, Scott; Kern, David; Sheehan, Neil; Screnci, Diane; Tifft, Doug; McNamara, Nancy; Schmidt, Wayne
Subject:
TMI dose analyses I spoke today (12/21) with the site Chemistry Manager and the Site ODCM Specialist to status/follow-up the positive environmental sample. My discussion indicated the following:
- 1) Based on the results of the environmental sample at 2240 meters (1.4 miles SE of site), the licensee calculated a projected dose of 0.0212 mrem to the teen lung and a dose of 1.957 E-4 mrem to child total body.
- 2) The licensee calculated the "worst case" offsite dose, based on use of real time meteorology, for the release of November 21, a teen lung dose of 0.0486 mrem and 0.041 mrem to child whole body at 1143 meters (0,71 miles to the southeast).
Maximum projected organ dose at this time is 0.64 % of the quarterly ODCM limit of 7.5 millirem and 0.3% of the annual ODCM limit of 15 millirem.
.Maximum projected whole body dose is 0.16 % of the 25 millirem annual ODCM limit.
3)As previously reported, the licensee had originally estimated a worst case (hypothetical) site boundary (bounding) total dose of 0.06 mrem.
These numbers compare to an ODCM limit of 7.5 millirem/quarter and 15 millirem/year organ and 25 millirem/yr total dose.
- 4) Today, (12/21) the licensee Chemistry Manager, and a representative of the site environmental sample contactor, met with the owner of the farm where the environmental sample station was located. The licensee reported the farm owner had no concerns with the information and appreciated the outreach.
The licensee was continuing to review data and review additional sample results. No other samples at this time show positive results. The results appear to be consistent.
We continue to closely follow the results and review licensee on-going analyses.
ron 71